Regenxbio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Regenxbio Inc 's ROA in the second quarter of 2026?
Regenxbio Inc recorded a cumulative net loss of $-196 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -43.38%.

However, within the Healthcare sector 533 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4040, from total ROA ranking in the first quarter of 2026 at 4420.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-16.47 %	-30.39 %	-2.3 %	1.17 %	1.92 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-196	-290	-194	-178	-176
Return On Assets (TTM)	-43.38 %	-60.82 %	-37.71 %	-34.42 %	-34.07 %
RGNX's Total Ranking	# 4040	# 4420	# 3836	# 3858	# 3866
Total Assets (TTM) in million	486	342	455	527	582
Seq. Total Assets Change	42.1 %	-24.82 %	-13.64 %	-9.46 %	18.42 %
Seq. Net Income Change	-	-	-	-	-

RGNX's 5 Years Annual ROA >> Back to RGNX Management Effectiveness >> Compare RGNX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 73
Sector	# 534
Overall	# 3842

Return On Assets Statistics
High	Average	Low
29.45 %	-20.87 %	-61.02 %
(Jun 30 2018)		(Mar 31 2026)

Financial Statements
Regenxbio Inc 's Assets	$ 486 million	RGNX's Balance sheet
Regenxbio Inc 's Income	$ 23 million	Quarterly RGNX's Income Statement
RGNX's Income by Division		See RGNX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-2.3 %	-18.9 %	-31.16 %	-25.06 %	52.68 %
Total Assets in million	455	466	575	835	1,114
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-194	-227	-263	-280	128
Annual Return On Assets	-42.58 %	-48.73 %	-45.85 %	-33.58 %	11.48 %

RGNX's 5 Years Annual ROA >> Back to RGNX Management Effectiveness >> Compare RGNX ROA to its Competitors

More Return On Assets Ratios
RGNX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RGNX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RGNX's Competitors
Subscribers only: Roa for Regenxbio Inc 's Suppliers
Subscribers only: Return On Assets for RGNX's Customers

You may also want to know
RGNX's Roi	RGNX's Inventory Turnover Ratio	RGNX's Growth Rates	RGNX's Dividend Comparisons
	RGNX's Profitability Ratios	RGNX's Asset Turnover Ratio	RGNX's Dividend Growth
RGNX's Roe	RGNX's Valuation Ratios	RGNX's Financial Strength Ratios	RGNX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:24:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.